A 24-week study to evaluate the safety and efficacy of CNTX-6970 in subjects with moderate to severe knee osteoarthritis pain

Knee osteoarthritis affects over 30% of older adults. Currently available medications have limited efficacy.
The study drug, CNTX-6970, is a highly selective CCR2 and CCR5 antagonist that has been shown to be effective in several animal models of OA. We conduct a phase 2 randomized, allocation-concealed, multi-center, placebo-controlled, crossover study to evaluate CNTX-6970 as a new treatment for painful osteoarthritis of the knee.

Principal investigators:

Brett Stacey (contact at UW site) and Michele Curatolo (UW site)
University of Washington